Table 3.
Target | Binding affinity (K d) | Year | Reference |
---|---|---|---|
Organic dyes | 100–600 μM | 1990 | [158] |
D-tryptophan | 18 μM | 1992 | [46] |
L-valine | 2.9 mM | 1994 | [159] |
Theophylline | 100 nM | 1994 | [44] |
Cyanocobalamin | 88 nM | 1994 | [160] |
L-citrulline | 62–68 μM | 1994 | [47] |
Flavin mononucleotide | 0.5 μM | 1994 | [161] |
Flavin adenine dinucleotide | 137–273 μM | 1994 | [161] |
Kanamycin A | ≤300 nM | 1995 | [162] |
Neomycin | 100 nM | 1995 | [163] |
Tobramycin | 2–3 nM | 1995 | [164] |
Lividomycin | ≤300 nM | 1995 | [162] |
Nicotinamide adenine dinucleotide | 2.5 μM | 1995 | [165] |
Riboflavin | 1–5 μM | 1995 | [165] |
Biotin | 5 μM | 1995 | [166] |
L-arginine | 330 nM | 1996 | [48] |
Dopamine | 2.8 μM | 1997 | [167] |
7-methyl-guanosine | 5 μM | 1997 | [168] |
CCdApPuro | 10 nM | 1997 | [169] |
Chloramphenicol | 25–65 μM | 1997 | [170] |
Viomycin | 11–21 μM | 1997 | [171] |
Sulforhodamine B | 310 nM | 1998 | [172] |
Streptomycin | 1–10 μM | 1998 | [173] |
L-isoleucine | 200–500 μM | 1998 | [174] |
7,8-dihydro-8-hydroxy-2′-deoxyguanosine (8-oxodG) | 0.27–2.8 μM | 1998 | [134] |
Xanthine | 3.3 μM | 1998 | [175] |
Guanine | 1.3 μM | 1998 | [175] |
Malachite green | ≤1 μM | 1999 | [176] |
Phosphatidylcholine | ≥100 μM | 1999 | [177] |
Cyclic adenosine monophosphate | 10 μM | 2000 | [178] |
Adenosine triphosphate | 127–223 μM | 2000 | [179] |
L-tyrosine | 35 μM | 2000 | [180] |
S-adenosyl homocysteine | 0.2–0.8 μM | 2000 | [181] |
Neomycin | 1.8 μM | 2000 | [182] |
Moenomycin A | 300–400 nM | 2001 | [183] |
Sialyl Lewis X | 0.085–10 nM | 2001 | [184] |
Tetracycline | 1 μM | 2001 | [185] |
Kanamycin B | 180 nM | 2001 | [186] |
Adenine | 10 μM | 2002 | [187] |
Flavin adenine dinucleotide | 50 μM | 2002 | [188] |
L-isoleucine | 1–7 mM | 2003 | [189] |
Adenosine triphosphate | 2 μM | 2003 | [190] |
Morpholine-based GTP analog | 20, 33 μM | 2003 | [191] |
4,4′-methylenedianiline | 0.45–15 μM | 2004 | [192] |
Tobramycin | 30–100 nM | 2004 | [34] |
Kanamycin | 10–30 nM | 2004 | [34] |
Adenosine triphosphate | 5 μM | 2004 | [193] |
Isoleucine | 0.9 mM | 2005 | [194] |
L-histidine | 8–54 μM | 2005 | [195] |
Codeine | 2.5–4 μM | 2006 | [33] |
Mesomesoprotoporphyrin IX | 188–445 nM | 2006 | [87] |
Thyroxine | 50 μM | 2007 | [196] |
Tobramycin | 16 μM | 2007 | [197] |
10-carboxy-2,7-di-t-butyl-trans-12c,12d-dimethyl-12c,12d-dihydrobenzo[e]pyrene | 2.7 μM | 2007 | [198] |
Dimethylindole red | 87 nM | 2008 | [199] |
Cyanine 3 dye | 60 μM | 2010 | [200] |
Aniline-substituted sulforhodamine analogue | 3.5 μM | 2010 | [201] |
Atrazine | 2 μM | 2010 | [202] |
Sphingosylphosphorylcholine | 20–250 nM | 2010 | [203] |
Black hole quencher | 4.7 μM | 2011 | [204] |
4-dimethylaminobenzylidene imidazolinone | 464 nM | 2011 | [205] |
Glutathione | 41.8, 48.9 nM | 2011 | [206] |
Heteroaryldihydropyrimidine | 50 nM | 2011 | [207] |
*Only aptamer sequences that have experimentally determined K d values were included in this table.